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Summary 
RNAi technologies are a valuable tool in the identification and investigation of proteins 
which are involved in peroxisome biogenesis and function. Small interfering RNA (siRNA) 
has developed into the most commonly used RNAi tool for the induction of transient, short-
term silencing of protein coding genes. Although siRNA can induce gene knockdown in a 
variety of mammalian cell lines, their utility is limited by efficient uptake of synthetic 
oligonucleotides into the cells. Here, we describe different transfection methods which have 
been successfully used by us to silence peroxisomal genes in a variety of cell lines, including 
primary human skin fibroblasts, which are usually difficult to transfect. 
 
1 Introduction 
Small (or short) interfering RNA (siRNA) represents a class of double-stranded RNA 
molecules, which specifically target a particular mRNA for degradation, thus resulting in 
gene silencing and knockdown of protein expression (1-3). siRNA acts via the RNA 
interference (RNAi) pathway, where it binds to protein complexes such as Dicer (which dices 
up siRNA into smaller fragments) and RISC (RNA-induced Silencing Complex), which leads 
to specific RNA cleavage and degradation (1-3). siRNA can act in RNAi-related pathways as 
an antiviral mechanism, but synthetic siRNAs can also induce RNAi in mammalian cells (4). 
Therefore, siRNA has developed into the most commonly used RNAi tool for the induction 
of transient, short-term silencing of protein coding genes.  
RNAi technologies have been proven to be a valuable tool in the identification and 
investigation of proteins which are involved in peroxisome biogenesis and function. One 
illustrative example is the discovery of a role for the dynamin-related protein 1 (DRP1), a 
large GTPase with mechanochemical properties, in peroxisomal fission (5-8). Efficient 
knockdown of DRP1 in cells of human and rodent origin was achieved with a conserved 
DRP1 target sequence corresponding to the coding region 783-803 (5, 7) (Fig. 1). 
Remarkably, silencing of DRP1, which localizes to both peroxisomes and mitochondria, 
resulted in a massive membrane elongation of peroxisomes (and mitochondria) due to a block 
in organelle division (5, 7) (Fig. 1). This characteristic peroxisomal morphology was later 
observed in patient fibroblasts and led to the discovery of DRP1 deficiency, the first member 
of a new group of disorders with defects in peroxisomal and mitochondrial division (9, 10). 
Although siRNA can induce gene knockdown in a variety of mammalian cell lines, their 
utility is limited by efficient uptake of synthetic oligonucleotides into the cells. Here, we 
describe different transfection methods which have been successfully used by us to silence 
peroxisomal genes in a variety of cell lines, including primary skin fibroblasts, which are 
usually difficult to transfect.  
 
2 Materials 
All reagents and equipment used to maintain and process living cells need to be sterile, and 
appropriate aseptic techniques and practices should be applied at all times. 
 
2.1 Mammalian Cells and siRNA 
1. Mammalian cell line of interest, here: human skin fibroblasts, HepG2 (human 
hepatoblastoma cells) (American Type Culture Collection ATCC HB-8065), COS-7 
(African green monkey kidney cells) (American Type Culture Collection CRL-1651). 
2. siRNA for silencing of candidate genes/proteins in mammalian cells, here: DRP1, 
ACBD5 (see Notes 1 and 2). 
 
2.2 Cell Culture Equipment 
1. Class II Biological Safety Cabinet/Tissue Culture Hood (see Note 3). 
2. Humidified CO2 incubator (95% air, 5% CO2, 37°C). 
3. Inverted light microscope (phase contrast). 
4. 37°C water bath. 
5. Mammalian cell counter. 
6. Vacuum aspiration system. 
7. Table top centrifuge equipped with a swing-out rotor for 15-ml conical tubes. 
8. Microporator Neon Transfection System, Invitrogen 
9. Electroporator BTX ECM 600 (630) (Harvard Apparatus), BTX, Holliston, MA, USA 
 
2.3 Cell Culture Media, Buffers, and Reagents 
1. Complete growth medium (for human skin fibroblasts and COS-7 cells): Dulbecco's 
modified Eagle’s medium (DMEM), high glucose (4.5 g/L) supplemented with 10% 
(v/v) fetal bovine serum (FBS), 2 mM Glutamine, 100 units/mL penicillin and 100 
µg/mL streptomycin (store at 4°C). For HepG2 cells: Minimum essential medium 
(MEM-Eagle, Earle’s salts) supplemented with 10% (v/v) fetal bovine serum (FBS), 2 
mM Glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin (store at 4°C).  
2. Phosphate-buffered saline (1×PBS) (without Ca2+ and Mg2+): 6.5 mM Na2HPO4, 1.5 
mM KH2PO4, 140 mM NaCl, 2.5 mM KCl, pH 7.4 (store at 4°C). 
3. TrypLE™ Express solution (1×) (Gibco) (store at 4°C) (see Note 4). 
4. 70% (v/v) ethanol. 
5. Clean and sterile glass coverslips (19 mm ∅, 0.13-0.17 mm thickness) (see Note 5). 
6. Metal tweezers 
 
2.4 Transfection with siRNA 
1. Neon Transfection Kit, Invitrogen. Store buffers at 4ºC. 
2. HEPES-buffered saline solution (HBS): 21 mM Hepes, 137 mM NaCl, 5 mM KCl, 
0.7 mM Na2HPO4, 6 mM dextrose, pH 7.15. Prepare fresh for transfection. 
3. 4 mm gap electroporation cuvettes (Molecular Bioproducts, Inc., San Diego, CA, 
USA). 
4. Lipofectamine 3000, Invitrogen. Store at 4ºC. 
5. Opti-MEM, Life Technologies. Store at 4ºC. 
6. siRNA in sterile, RNase/DNase-free water or buffer supplied by manufacturer (50 – 
100 µM stock). 
 
2.5 Controls 
Controls are an essential part of every siRNA experiment. It is recommended to add a 
positive control, a negative control and an untreated control. A well-characterized positive 
control allows ensuring the experimental set-up (e.g. transfection method, cell line used) is 
sufficient to achieve effective silencing. We usually include DRP1-specific siRNA as a 
positive control, which results in a characteristic elongation of peroxisomes (11-14) (Fig. 1). 
This morphological alteration can easily be detected by immunofluorescence using 
peroxisomal marker proteins (Fig. 1). Negative controls help to distinguish sequence-specific 
effects from the effects of experimental conditions on cellular responses. An untreated 
control serves as a useful reference for cell and organelle phenotypes and gene expression 
levels. To exclude off-target effects, different and optimised siRNAs can be used (see Note 
2). 
 
Place Fig. 1 here 
 
3 Methods 
 3.1 Cell Culture 
1. Perform all cell culture related work in a Class II Biological Safety Cabinet/Tissue 
Culture Hood and disinfect the work surface and materials (e.g., pipettes) with 70% 
(v/v) ethanol. 
2. Grow mammalian cells of choice (here, human skin fibroblasts, HepG2, or COS-7 
cells) in complete growth medium (10 cm ∅ cell culture dishes) in a humidified CO2 
incubator (95% air, 5% CO2, 37°C). 
3. Refresh the cell culture medium every 2-3 days. 
4. Split the cells before they reach 100% confluency (see steps 4 to 14). 
5. Pre-warm 1×PBS, TrypLE™ Express solution, and complete growth medium to 37°C. 
6. Remove all medium from the cell culture dish with a Pasteur pipette by vacuum 
aspiration and wash the cells once with 4 mL of 1×PBS. 
7. Add TryplExpress solution to the cells and gently tilt to cover the surface (1 mL/10 
cm dish). 
8. Incubate the cells for 2-5 min at 37°C. 
9. Upon detachment, harvest the cells in complete growth medium (10 mL/10 cm dish). 
10. Carefully resuspend the cells by pipetting the cell suspension 2-3 times up and down 
and further detach remaining cells from the surface of the dish.  
11. Transfer the cells to a 15-mL conical tube and take an aliquot of the suspension for 
cell counting. 
12. Pellet the cells by centrifugation (500×g, 3 min at RT). 
13. Resuspend the cell pellet in 10 mL of complete growth medium. 
14. For maintenance, transfer the required amount of cells (approx. 5×105 cells) to a new 
10 cm cell culture dish containing 10 mL of complete growth medium (see step 4). 
15. Incubate the cells in a humidified CO2 incubator (95% air, 5% CO2, 37°C). 
3.2 Transfection of siRNA into human skin fibroblast using microporation 
1. Split an appropriate amount of cultured human fibroblasts 24 hours before 
transfection and seed 4×105 cells per 10 cm ∅ culture dish. This amount of cells is 
required for one transfection using the 100 µl Neon tip (see Note 6). Prepare 
additional 10 cm dishes as required. Always include a control. It is advisable to 
prepare 1-2 extra dishes as a backup (4×105 cells per dish). 
2. On the day of transfection, add 4 ml complete growth medium (without antibiotics!) 
into a 6 cm ∅ culture dish and place in the incubator (see Note 7). For each 
microporation, a 6 cm ∅ dish is required. For analysis by immunofluorescence, add 4 
sterile, clean glass coverslips to the dish prior to adding the medium using sterile 
tweezers. We routinely use round coverslips (19 mm ∅, 0.13-0.17 mm thickness). 
Coverslips are not required for analysis by immunoblotting. 
3. Harvest the cells by trypsination, pool them and centrifuge at 500×g for 3 min. 
4. Aspirate the supernatant, resuspend the cell pellet in 1×PBS, and centrifuge as above. 
5. During centrifugation, place the Neon Microporation device in the biological safety 
cabinet. Fill a Neon tube with 3 ml of electrolyte buffer E2 and insert the tube into the 
Pipette station. Set the pulse conditions (here, 1400 V, 20 ms pulse width, 1 pulse) on 
the device (see Notes 8 and 9). 
6. Aspirate the supernatant, and resuspend the cell pellet in R-buffer (add 110 µl R-
buffer per 4×105 cells) (see Note 10). Gently transfer the cells into a sterile 1.5 ml 
microcentrifuge tube. 
7. Add 100 nM siRNA into another sterile 1.5 ml microcentrifuge tube (see Note 11) 
8. Gently add 110 µl of cell suspension (in R-buffer) and pipette 1-2 times up and down. 
9. Mount a 100 µl Neon tip onto the Neon pipette. 
10. Immerse the tip into the cell-siRNA mixture and slowly aspirate 100 µl of the sample. 
Avoid generating air bubbles in the tip. 
11. Insert the pipette into the E2 buffer-containing tube in the pipette station, and press 
start on the touch screen. 
12. After delivery of the electric pulse, remove the pipette from the pipette station and 
immediately transfer the cells from the tip to the 6 cm dishes containing the 
prewarmed growth medium (without antibiotics) (see Note 12). 
13. Gently move the dish horizontal and vertical to evenly distribute the cells (see Note 
13). 
14. Incubate the cells in a humidified CO2 incubator (95% air, 5% CO2, 37°C) for 72 
hours to allow efficient silencing (see Note 14). 
15. Discard the Neon tip in an appropriate biological hazardous waste container and 
repeat steps 7 to 15 for the remaining cell-siRNA mixtures (control siRNA and other 
siRNA samples) (see Note 15). 
16. Cells are usually assayed for protein level and peroxisome morphology by indirect 
immunofluorescence and standard immunoblotting of cell lysates (Fig. 2). 
 
Place Fig 2 here (or alternatively at the end before the Notes) 
 
3.3 Transfection of siRNA into mammalian cells using electroporation 
1. Split an appropriate amount of cultured COS-7 or HepG2 cells 48 hours before 
transfection and grow to 80-90% confluency on an area of 75 cm2/flask or 10 cm ∅ 
culture dish. 
2. On the day of transfection, harvest the cells (1×107) by trypsination and centrifuge at 
500×g for 3 min (see Note 16). 
3. Resuspend the cell pellet in 10 mL HEPES-buffered saline solution (HBS), centrifuge 
as above and resuspend the cell pellet in 0.5 mL HBS. 
4. Transfer the sample to a 0.4 cm gap, sterile electroporation cuvette containing 20-50 
µl of siRNA (20 µM) and mix quickly by pipetting. 
5. Place the cuvette in the electroporator and perform the electroporation using the 
following settings: 230 V (use 250 V for HepG2 cells), 1500 µF, 129 Ω, 25–30 ms 
duration (see Note 17).  
6. After electroporation, immediately resuspend the cells in 1 mL of complete growth 
medium. Discard the viscous foam produced during electroporation. Dilute in pre-
warmed growth medium and plate the cells in 6 cm ∅ dishes (see Note 18). For 
analysis by immunofluorescence, add 4 sterile, clean glass coverslips to the dish prior 
to adding the medium using sterile tweezers. We routinely use round coverslips (19 
mm ∅, 0.13-0.17 mm thickness). Coverslips are not required for analysis by 
immunoblotting. Coating of the cover slips/dishes (e.g. with collagen) can improve 
attachment.  
7. Cells are usually assayed for protein level and peroxisome morphology after 2-3 days 
by indirect immunofluorescence and standard immunoblotting of cell lysates (see 
Note 19) (Figs. 1, 2). 
 
Using the transfection protocol described, we routinely obtain transfection efficiencies 
between 70 and 80%. Re-transfection is not required.  
 
3.4 Transfection of siRNA into mammalian cells using lipofection 
1. Split an appropriate amount of cultured HepG2 cells 24 hours before transfection and 
seed 250,000 cells on collagen-coated 6 cm ∅ culture dishes. For analysis by 
immunofluorescence, add 4 sterile, clean glass coverslips to the dish prior to adding 
the growth medium. 
2. On the day of transfection, add 3.3 µL siRNA (from 50 µM stock) to 250 µL Opti-
MEM in a 1.5 mL microcentrifuge tube. In a second microcentrifuge tube, add 17 µL 
Lipofectamine 3000 to 250 µL Opti-MEM. Pipet the siRNA mix to the Lipofectamine 
mix. Gently pipet up and down 3-4 times and incubate for 5 min. at room temperature. 
The mixture is sufficient for transfection of one 6 cm ∅ culture dish. 
3. Meanwhile, wash the cells once with PBS and add 3.5 mL of fresh complete growth 
medium.  
4. Add the siRNA/Lipofectamine mix dropwise to the cells and incubate in a humidified 
CO2 incubator (95% air, 5% CO2, 37°C) for 72 hours to allow efficient silencing. 
5. Cells are usually assayed for efficient silencing by indirect immunofluorescence and 
standard immunoblotting of cell lysates (Figs. 1, 2). Using the transfection protocol 
described, we routinely obtain transfection efficiencies between 70 and 80%. 
Electroporation (see 3.3) or microporation (15) are alternative transfection methods 
for HepG2 cells. 
 
4. Notes 
1. Gene silencing in mammalian cultured cells can be achieved by DNA-directed RNAi, in 
which a DNA vector is used to express short hairpin RNAs, or by directly introducing 
small, interfering RNA duplexes (siRNA) into target cells. Chemically synthesized small 
oligonucleotide siRNA duplexes are usually easier to transfect than DNA-based vectors 
that express siRNA. 
2. Synthetic siRNAs are most commonly generated through solid-phase chemical synthesis 
methods (e.g. 2'-ACE chemistry) providing highly pure, stable, and readily modified 
siRNAs. Several manufacturers offer support in siRNA design and provide optimized and 
validated siRNAs and appropriate controls. siRNAs can also be used for knockdown of 
non-protein coding genes, such as long noncoding RNAs. 
3. Follow the biosafety and GMO guidelines of your institution. 
4. TrypLE™ Express (12604013, Gibco) is an animal origin-free, RT-stable, recombinant 
enzyme suitable for the dissociation of a wide range of adherent mammalian cells. It 
cleaves peptide bonds on the C-terminal sides of lysine and arginine, and is a direct 
replacement for trypsin. Its high purity increases specificity and reduces damage to cells 
that can be caused by other enzymes present in some trypsin extracts. Alternatively, 
Trypsin/EDTA solution (1x) can be used: 0.05% (w/v) trypsin, 0.68 mM EDTA, 5.5 mM 
glucose, 137.93 mM NaCl, 5.36 mM KCl, 6.9 mM NaHCO3 (store at -20°C). 
5. For sterilisation, glass coverslips are put in a glass petri dish, wrapped in tin foil and dry-
sterilised for 6 h at 180°C. 
6. Splitting the cells 24 hours prior to transfection is important to avoid stress due to high 
cell density. Furthermore, cell counting on the day of transfection is not required anymore 
and will reduce the handling time of the cells during the transfection procedure. 
7. The addition of antibiotics to the growth medium can drastically reduce the viability of 
freshly transfected cells. 
8. A detailed instruction manual of how to use the Neon device can be downloaded from the 
supplier’s website 
(http://tools.thermofisher.com/content/sfs/manuals/neon_device_man.pdf). 
9. Pulse conditions for other cell types need to be optimized. Further information is provided 
on the supplier’s website (https://www.thermofisher.com/be/en/home/life-science/cell-
culture/transfection/transfection---selection-misc/neon-transfection-system/neon-
protocols-cell-line-data.html). 
10. We use 10% more R-buffer (110 µl instead of 100 µl) to compensate for pipetting errors 
and to avoid aspiration of air. 
11. Use conical 1.5 ml microcentrifuge tubes instead of round bottom 2 ml microcentrifuge 
tubes to avoid generation of air bubbles. 
12. In case of an electric spark during the electric pulse (due to potential air bubbles), discard 
the tip with the cells and repeat the microporation using the backup cells. 
13. Do not swirl, as this will lead to the accumulation of the cells in the center of the dish. 
14. Based on our experience, a change of the growth medium during the 72 hours incubation 
period is not required. 
15. The Neon pipette tips and tubes can be regenerated and reused as described (16), thereby 
reducing the cost of microporation at least 10-fold. 
16. Electroporation can result in high transfection rates and usually requires non-adherent 
cells (e.g. suspension cultures or trypsination of adherent cells). However, a dish-
electrode for in-dish transfection of adherent cells is as well available (BTX Harvard 
Apparatus). 
17. Electroporation of siRNA typically requires optimization of various parameters that affect 
cell uptake and cell viability (e. g., electroporation medium, cell number, voltage, 
capacitance, resistance). It is advisable to test siRNA efficiency at various time points 
after transfection. 
18. Cells can also be plated in 6-well plates (2×105 cells/well). 
19. Analysis of peroxisome morphology and siRNA efficiency is facilitated by the use of 
cells stably expressing a fluorescent fusion protein bearing a peroxisomal targeting signal 
(e. g., GFP-PTS1, DsRed-PTS1) (7). 
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Figure legends 
 
Figure 1. siRNA-mediated silencing of the dynamin-like fission GTPase DRP1/DLP1 
induces peroxisomal membrane elongation. COS-7 cells stably expressing a fusion of GFP 
and a peroxisomal targeting signal (GFP-PTS1) were transfected with DRP1 siRNA using 
lipofection and processed for immunofluorescence with anti-DRP1 antibodies 48 hours after 
transfection. (A, B) Localisation of peroxisomes (green) and DRP1 (red). DRP1 is efficiently 
silenced in cells that took up the DRP1 siRNA (A) (asterisks). Note the untransfected, non-
silenced cell on the right, which shows strong labeling for DRP1 in the cytoplasm and 
contains spherical instead of elongated peroxisomes. (B) Higher magnification view of 
elongated, constricted peroxisomes (arrows) after efficient silencing of DRP1. DRP1 is not 
efficiently silenced in the cell on the left (x). N, nucleus. (C) Immunoblots of peroxisomal 
fractions isolated from controls (Con) and cells transfected with DRP1 siRNA using anti-
PMP70 (peroxisomal membrane protein) and anti-DRP1 antibodies. Equal amounts of 
protein (PMP70, 10 µg/lane; DRP1, 45 µg/lane) were loaded onto the gel (taken from (7) 
with kind permission of the Company of Biologists). Bars, 10 µm. 
 
Figure 2. siRNA-mediated silencing of ACBD5, a peroxisomal acyl-CoA binding domain 
protein, in patient skin fibroblasts. (A, B) Human skin fibroblasts from a patient with a defect 
in Mff, a membrane adaptor for DRP1 at peroxisomes (and mitochondria) (17-19) were 
transfected with ACBD5-specific or control siRNA using microporation and processed for 
immunofluorescence with anti-ACBD5 and anti-catalase (aCAT) antibodies 72 hours after 
transfection. (A) ACBD5 co-localises with the peroxisomal marker protein catalase in 
controls cells. Note that peroxisomes in Mff-deficient cells are highly elongated due to a 
block in membrane fission. (B) ACBD5 is efficiently silenced in cells that took up the 
ACBD5 siRNA. Occasionally, some residual ACBD5 is visible at peroxisomes. (C) 
Immunoblots of cell lysates from controls (scrambled siRNA) and cells transfected with 
ACBD5 siRNA using anti-ACBD5 and anti-tubulin antibodies. Equal amounts of protein 
were loaded onto the gel. Tubulin served as a loading control. Bars, 10 µm. 
